Glr study | Science homework help

1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). Your firm’s investigations of out-of-specification (OOS) results were closed without adequate scientific justification. For example, you opened an OOS investigation for (b)(4) USP active pharmaceutical ingredient (API) for an unknown impurity which exceeded your specification. Your investigation identified an “old reagent” as a root cause, despite your inability to reproduce the unknown impurity. You subsequently retested a new sample with fresh reagents and used the passing results to release the API for use in producing your (b)(4) USP drug product. You did not evaluate the original failing API sample. Your root cause determination and investigation were not scientifically justified. In your response you acknowledged that the original sample should have been tested as part of your investigation to determine a root cause and that the final root cause was not definitively concluded. You analyzed reserve samples for the lots of drug product manufactured with the API and found them to meet specifications. You also provided a retrospective review for all of your previous “invalidated” OOS results for products manufactured between January 2017 and March 2019. Your response is inadequate. You failed to include the data that supports your reserve sample testing for batches manufactured containing the lot of API identified in your OOS investigation. In addition, you identified nine additional OOS investigations in which your root cause determination and investigation were not scientifically justified. You did not extend your investigation to include any associated reserve samples of batches that may have been manufactured using OOS materials. In response to this letter:

For any OOS results with inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, raw materials, process capability, deviation history, batch failure history). Provide a corrective action and preventive action (CAPA) plan that identifies root causes and specifies meaningful improvements. Provide all reserve sample testing results. Include all analytical data for the API and drug product batches, including any batches manufactured using API with associated OOS results with inconclusive or no root cause. For more information about proper handling of OOS results and documenting your investigations, refer to the FDA guidance for industry Investigating OOS Test Results for Pharmaceutical Production at https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070287.pdf (h�ps://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInforma�on/Guidances/UCM070287.pdf) Data Integrity Remediation 1/12/2020 Strides Pharma Science Limited - 576722 - 07/01/2019 | FDA https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strides-pharma-science-limited-576722-07012019 4/5 Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP-compliant data integrity practices at https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM495891.pdf (h�ps://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInforma�on/Guidances/UCM495891.pdf) We strongly recommend that you retain a qualified consultant to assist in your remediation.

In response to this letter, provide the following:

A. An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses. B. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations. C. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm, including microbiological and analytical data, manufacturing records, and all data submitted to FDA. Conclusion Violations cited in this letter are not intended as an all-inclusive list. You are responsible for investigating these violations, for determining the causes, for preventing their recurrence, and for preventing other violations in all your facilities. If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at [email protected], so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b) and allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products. Until you correct all violations completely and we confirm your compliance with CGMP, FDA may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. Failure to correct these violations may also result in FDA refusing admission of articles manufactured at Strides Pharma Science Limited, FEI 3012448465, at Unit-II, R. S. No.: 32, 33 & 34 PIMS Road Periyakalapet, Puducherry into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Under the same authority, articles may be subject to refusal of admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B). After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. Send your electronic reply to [email protected] (mailto:CDER-OC-OMQ-

Communica�[email protected]) or mail your reply to:

Carla Norris Compliance Officer 1/12/2020 Strides Pharma Science Limited - 576722 - 07/01/2019 | FDA https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strides-pharma-science-limited-576722-07012019 5/5 U.S. Food and Drug Administration White Oak Building 51, Room 4359 10903 New Hampshire Avenue Silver Spring, MD 20993

USA

Please identify your response with FEI 3012448465. Sincerely,

/S/

Francis Godwin Director Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research cc: Mr. Umesh Kale President & Chief Quality Officer Strides Pharma Science Limited Strides House, Bilekahalli Bannerghatta Road Bangalore 560076 India More Warning Letters (/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)

• Powerpoint presentation RELIGON CLASS
• leadership teamwork consultant
• Discussion Questions 2
• Chapter 9 Review
• American Literature 1 page paper
• Racial Profiling
• (2)
• reading assignment.
• Write one-page summary on: Dr. Jay Kunzeâs presentation on âNuclear Engineering.â
• HR Challenges in Relation to People and Technology